Read if you want one stock you can retire on

Search

brucefan

Active member
Joined
Jan 19, 2005
Messages
3,139

Status Update to Shareholders from Rafarma Pharmaceuticals, Inc.​

November 08, 2021 10:43 ET | Source: RAFARMA PHARMACEUTICALS INC







  • ...
Nicosia, Cyprus, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) provides the following update to shareholders:
The company is continuing its PCAOB auditing process, and, after input from accounting, legal and business consultants, is changing the planned auditing years to 2020 and 2021. This decision comes not only because of business factors (e.g., pandemic delays, significant changes in international tax legislation and legislation in the target markets of the company, as well as other several objective factors) but also because the audited information will be more current and will more thoroughly showcase the company’s business strength to the public market. Other than changing audit years, the process will continue and enable Rafarma to apply for uplisting on a major market platform. As always, our goal is to build a well-calibrated business operations and market transparency.
Additionally, we are pleased to announce that R.& D. BIOCOGENCY LABORATORIES INC. LTD will complete a $9.5 million capital infusion to Rafarma by the end of 2021. The cash will be used to finance current costs for consultants, scientific laboratories, contactors, and project organizations, as well as to finance the previously-announced project in Uzbekistan.
In addition, the progress on R&D projects in Turkey and Thailand continues, with further updates to follow.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
RAFARMA-PHARMACEUTICALS-INC.png
 

CoachCB

Active member
Joined
Feb 28, 2005
Messages
8,779

Status Update to Shareholders from Rafarma Pharmaceuticals, Inc.​

November 08, 2021 10:43 ET | Source: RAFARMA PHARMACEUTICALS INC







  • ...
Nicosia, Cyprus, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) provides the following update to shareholders:
The company is continuing its PCAOB auditing process, and, after input from accounting, legal and business consultants, is changing the planned auditing years to 2020 and 2021. This decision comes not only because of business factors (e.g., pandemic delays, significant changes in international tax legislation and legislation in the target markets of the company, as well as other several objective factors) but also because the audited information will be more current and will more thoroughly showcase the company’s business strength to the public market. Other than changing audit years, the process will continue and enable Rafarma to apply for uplisting on a major market platform. As always, our goal is to build a well-calibrated business operations and market transparency.
Additionally, we are pleased to announce that R.& D. BIOCOGENCY LABORATORIES INC. LTD will complete a $9.5 million capital infusion to Rafarma by the end of 2021. The cash will be used to finance current costs for consultants, scientific laboratories, contactors, and project organizations, as well as to finance the previously-announced project in Uzbekistan.
In addition, the progress on R&D projects in Turkey and Thailand continues, with further updates to follow.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
RAFARMA-PHARMACEUTICALS-INC.png

I bought a small amount of RAFA. I'm down 58%. This is one of those all-or-bust for me stocks.
 

brucefan

Active member
Joined
Jan 19, 2005
Messages
3,139
Rafa is going to make us alot of money. Taking longer, but just gives us more time to build our positions
 

brucefan

Active member
Joined
Jan 19, 2005
Messages
3,139
*RAFA* Company “Rafarma Pharmaceuticals Inc.” Combined Financial statements for the period ended, September 30, 2021

Third Quarter Results

Financial Highlights Q3
$51.3 Million in Sales

$18.2 Million Gross Profits
$7.24 Million Income after Taxes

$0.082c Earnings Per Share

$12.4 Million in Cash
87.7 Million Shares Outstanding [unchanged]

Disclosure Statement Q3
 

brucefan

Active member
Joined
Jan 19, 2005
Messages
3,139
From SAA ADV

Predictive Technology Group (PRED) .058

Jan 6th 2022 PRED and HLTT entered into a binding term sheet.
The agreement calls for the formation of a subsidiary (Newco) that
will acquire the assets of the Biotech Division related to wound care. The transfer of the wound care asset to (Newco) , PRED will receive shares representing 30% of the equity in Newco. Various amounts of
$ will be loaned to PRED as numerous milestones near term are met.
Loan will be paid back from gross income from sales of Wound Care products.

Please visit HLTT and review the 8K that was released by Healthtech Solutions (HLTT).

There are additional options that are mentioned within the just released document. The newly formed company (Newco) can purchase additional assets from the Biotech Division, but does not include Stem Cells.
We assume additional info will be forthcoming near term as additional
terms becomes available with a week or so.
We believe that this development is a very important development for PRED not only to survive, but to thrive.

THE GLOBAL WOUND CARE MARKET IS EXPECTED TO REACH NEARLY US$34 BILLION BY 2026!

The potential for PRED to turn itself around from this newly formed
agreement could easily be a game changer. This could allow PRED to pursue continued development of their Endometriosis and Infertility test kits and potentially take their Stem Cell products Internationally.
It has been a disappointing ride with PRED over the past 2 years, but
the game is not over. If you still believe and still own this "fallen Angel" one might considering to average down. If new to this situation it might be an excellent price point to enter for a trade or even a longer term speculation.

The Newco wound care product, Amniobind, next generation Amniobind and injectable regenerative medicine products are the only assets being acquired. If you have interest in reviewing information concerning Amniobind please visit www.predtechgroup.com

PS: We have heard that the company will compy with SEC filings in
order to stay current. They also just filed their 8K concerning this noted transaction. (2 pm MST Jan 6th 2022)
**************************************************
 

vinnyvegas

F me, F U
Joined
Oct 15, 2004
Messages
2,407
From SAA ADV

Predictive Technology Group (PRED) .058

Jan 6th 2022 PRED and HLTT entered into a binding term sheet.
The agreement calls for the formation of a subsidiary (Newco) that
will acquire the assets of the Biotech Division related to wound care. The transfer of the wound care asset to (Newco) , PRED will receive shares representing 30% of the equity in Newco. Various amounts of
$ will be loaned to PRED as numerous milestones near term are met.
Loan will be paid back from gross income from sales of Wound Care products.

Please visit HLTT and review the 8K that was released by Healthtech Solutions (HLTT).

There are additional options that are mentioned within the just released document. The newly formed company (Newco) can purchase additional assets from the Biotech Division, but does not include Stem Cells.
We assume additional info will be forthcoming near term as additional
terms becomes available with a week or so.
We believe that this development is a very important development for PRED not only to survive, but to thrive.

THE GLOBAL WOUND CARE MARKET IS EXPECTED TO REACH NEARLY US$34 BILLION BY 2026!

The potential for PRED to turn itself around from this newly formed
agreement could easily be a game changer. This could allow PRED to pursue continued development of their Endometriosis and Infertility test kits and potentially take their Stem Cell products Internationally.
It has been a disappointing ride with PRED over the past 2 years, but
the game is not over. If you still believe and still own this "fallen Angel" one might considering to average down. If new to this situation it might be an excellent price point to enter for a trade or even a longer term speculation.

The Newco wound care product, Amniobind, next generation Amniobind and injectable regenerative medicine products are the only assets being acquired. If you have interest in reviewing information concerning Amniobind please visit www.predtechgroup.com

PS: We have heard that the company will compy with SEC filings in
order to stay current. They also just filed their 8K concerning this noted transaction. (2 pm MST Jan 6th 2022)
**************************************************
Interesting. Thx for posting Brucefan
 

Forum statistics

Threads
1,024,376
Messages
12,737,785
Members
94,811
Latest member
maggawyld